2023
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2023, 33: 20-26. PMID: 36799961, DOI: 10.1089/cap.2022.0086.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression symptom improvementAcute dissociative symptomsAntidepressant responseSymptom improvementRapid-acting antidepressant agentsSignificant associationDissociative symptomsLikelihood of responseDissociation symptomsMagnitude of associationDissociative effectsKetamine groupPediatric patientsCrossover trialPediatric populationAntidepressant agentsKetamine responseAdolescent patientsAdult studiesDepression responseSecondary data analysisTreatment responseDepressive symptomsTrial design
2021
A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome
Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF. A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome. Journal Of Neuropsychiatry 2021, 33: 328-336. PMID: 34340527, DOI: 10.1176/appi.neuropsych.19080178.Peer-Reviewed Original ResearchConceptsTourette syndromeTic symptomsUncontrolled trialsYale Global Tic Severity Scale-Total Tic ScoreDouble-blind placebo-controlled trialAvailable evidence-based treatmentsPhase 2 pilot studyExtension phasePlacebo-controlled trialRefractory Tourette syndromeTotal tic scoreEffective pharmacological treatmentCannabis-derived compoundsEvidence-based treatmentsTHC dosingSecondary outcomesPrimary outcomeComorbid conditionsPharmacological treatmentTic scoreYGTSS scoresTherapeutic combinationsSide effectsTrial designSyndrome
2017
Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis.
Stuckelman ZD, Mulqueen JM, Ferracioli-Oda E, Cohen SC, Coughlin CG, Leckman JF, Bloch MH. Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis. The Journal Of Clinical Psychiatry 2017, 78: e648-e655. PMID: 28682529, DOI: 10.4088/jcp.15r10601.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderRisk of irritabilitySide effectsPsychostimulant medicationPsychostimulant treatmentAmphetamine derivativesPlacebo-controlled trialCommon side effectsStratified subgroup analysisEffects of amphetamineTreatment of childrenDuration of usePsychostimulant classesEligible trialsMedical comorbiditiesHead trialsSubgroup analysisRisk ratioRelative riskSTUDY SELECTIONEffective treatmentDATA SOURCESPubMed searchTrial designStimulant type
2015
Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder
Coughlin CG, Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Bloch MH. Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder. Journal Of Child And Adolescent Psychopharmacology 2015, 25: 611-617. PMID: 26402485, PMCID: PMC4617411, DOI: 10.1089/cap.2015.0075.Peer-Reviewed Original ResearchConceptsRisk of anxietyAttention-deficit/hyperactivity disorderPsychostimulant treatmentSide effectsHyperactivity disorderPlacebo-controlled trialStratified subgroup analysisTreatment of childrenDuration of useRisk ratioSubgroup analysisPsychostimulant medicationPlaceboPubMed searchTrial designNumber of childrenHigh dosesStimulant typePsychostimulantsAnxiety symptomsTreatmentChildrenRiskSymptomsAnxiety
2012
Pharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias
Carrasco M, Volkmar FR, Bloch MH. Pharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias. Pediatrics 2012, 129: e1301-e1310. PMID: 22529279, PMCID: PMC3340598, DOI: 10.1542/peds.2011-3285.Peer-Reviewed Original ResearchConceptsSerotonin receptor inhibitorsPublication biasTrial resultsPlacebo-controlled trialAutism spectrum disorderRepetitive behaviorsAvailable medicationsPatient agePharmacologic treatmentPrimary outcomeUnpublished trialsEgger's testReceptor inhibitorsMean improvementSpectrum disorderFunnel plotTrial designSecondary analysisTrial durationRating ScaleEfficacyTrialsTweedie's trimMedicationsTreatment